Drug Topics

Drug Topics is a unique news magazine that covers every aspect of pharmacy for community, independent, retail, and hospital pharmacists. Its main aim is to keep busy pharmacists updated and ready for the latest clinical, professional, business, legal, and governmental changes that impact their practices, all presented in a straightforward and digestible format. Besides offering valuable clinical insights for health-system pharmacists and those in both hospital and community environments, Drug Topics also provides essential business, financial, and regulatory guidance tailored for community pharmacists, whether they operate independently or as part of a chain.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#758331

United States

#261473

Health/Pharmacy

#508

Traffic sources

Monthly visitors

Articles

FDA Approves Dupilumab for Treatment of Chronic Spontaneous Urticaria

6 days ago | drugtopics.com | Ashley Gallagher

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria (CSU) who are symptomatic despite histamine-1 antihistamine treatment.1 “CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living,” Alyssa Johnsen, MD, PhD, global therapeutic head of immunology and oncology development at Sanofi, said in a news release.1 “This FDA approval provides a new treatment option to help...
Q&A: Expert on Social Media’s Normalization of Lifestyle Drugs

6 days ago | drugtopics.com | Brian Nowosielski |Luke A. Turnock

Luke Turnock, PhD, MSc, has done extensive research on prescription drug markets and how these products have been promoted on social media in recent history. He’s specifically versed in the promotion of weight-loss medications, testosterone replacement therapy (TRT), and sexual enhancement products. Throughout his research, he and his colleagues have uncovered an alarming normalization of these products that can potentially lead to poor outcomes for many consumers globally.
Minocycline Foam Significantly Improves Papulopustular Rosacea Outcomes

6 days ago | drugtopics.com | Brian Nowosielski

Topical minocycline foam significantly reduced inflammatory skin lesions and improved Investigator Global Assessment (IGA) scores among patients with papulopustular rosacea (PPR), according to data published in Frontiers in Medicine.1“PPR, one of the subtypes of rosacea, presents with unremitting centrofacial erythema along with the eruption of papules and pustules,” wrote the authors of the study.
ACIP Votes to Recommend Vimkunya for Prevention of Chikungunya Virus

6 days ago | drugtopics.com | Ashley Gallagher

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to recommend a single dose of the chikungunya vaccine, recombinant (Vimkunya), for the prevention of disease caused by the chikungunya virus.
ACIP Votes to Expand RSV Vaccine Recommendation to Include Adults 50 Years and Older

1 week ago | drugtopics.com | Ashley Gallagher

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to expand the recommended use of the respiratory syncytial virus (RSV) vaccine currently approved for adults aged 50 to 59 years who are at an increased risk of RSV-associated lower respiratory tract disease (LRTD).
ACIP Votes to Recommend the Use of MenABCWY in Adolescent Vaccine Schedule

1 week ago | drugtopics.com | Ashley Gallagher

The CDC Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of meningococcal groups A, B, C, W, and Y vaccine (Penmenvy) as part of the adolescent meningococcal vaccination schedule. The recommendation states that patients older than 10 years receive a single dose of Penmenvy as an alternative to separate administration of meningococcal serogroups A, C, W, and Y (MenACWY) and meningococcal serogroup B (MenB) vaccinations.
Executive Order to Limit PBM Control, Lower Drug Costs

1 week ago | drugtopics.com | Brian Nowosielski

The Trump Administration signed an executive order designed to lower prescription drug costs in the US, according to the White House.1 With provisions limiting pharmacy benefit manager (PBM) control and encouraging competition and innovation, the order is intended to benefit patients the most.
Subgroup Analysis Confirms Safety, Efficacy of Icotrokinra for Plaque Psoriasis

1 week ago | drugtopics.com | Ashley Gallagher

New data show icotrokinra (JNJ-2113) is efficacious and safe as a systemic therapy in both adolescents and adults, according to a phase 3 registrational study for moderate-to-severe plaque psoriasis.
Skin of Color Dermatology Substantially Improved in Last 20 Years

1 week ago | drugtopics.com | Brian Nowosielski

Advancements in skin of color (SOC) dermatology have markedly improved over the past 20 years, according to an analysis from the Journal of the American Academy of Dermatology Reviews.1 Despite notable improvements in the understanding and management of skin conditions among minority populations, researchers believe more advancements need to be made.
FDA Approves Diazepam Nasal Spray for Treatment of Seizure Clusters in Pediatric Patients

1 week ago | drugtopics.com | Ashley Gallagher

The FDA approved diazepam nasal spray (Valtoco) for the short-term treatment of acute repetitive seizures, also known as seizure clusters, which differ from a patient’s normal seizure pattern.